| May 8, 2026 | other | Bristol-Myers Squibb shareholders elected directors, approved executive compensation, and a 2026 stock award plan at the annual meeting. |
|---|
| Apr 30, 2026 | earnings | Bristol Myers Squibb reported Q1 2026 revenues of $11.5 billion and non-GAAP EPS of $1.58. |
|---|
| Feb 5, 2026 | earnings | Bristol Myers Squibb announced Q4 and full-year 2025 financial results, 2026 guidance, and increased its quarterly dividend to $0.63. |
|---|
| Apr 30, 2026 | Guidance: effective_tax_rate | 18.00 to not reported |
|---|
| Apr 30, 2026 | Guidance: gross_margin_percent | 69.00 to 70.00 |
|---|
| Apr 30, 2026 | Guidance: non_gaap_diluted_eps | 6.05 to 6.35 |
|---|
| Apr 30, 2026 | mda_quarterly | Bristol-Myers Squibb reported a 3% increase in total revenues to $11.49 billion for Q1 2026, or 1% excluding foreign exchange impacts. GAAP diluted EPS rose to $1.31, driven by lower amortization of acquired intangible assets, though partially offset by higher IPRD impairment charges and the expiry of diabetes royalty income. Non-GAAP EPS decreased to $1.58, primarily due to the diabetes royalty expiry.
The Growth Portfolio saw strong performance from Opdivo Qvantig, Camzyos, Breyanzi, Reblozyl, Opdualag, Sotyktu, and Cobenfy, all experiencing significant demand-driven increases. Eliquis revenues grew 16% due to U.S. demand, but faces generic competition in Europe and the Inflation Reduction Act's (IRA) "maximum fair price" in U.S. Medicare. Legacy products like Revlimid, Pomalyst/Imnovid, Sprycel, and Abraxane experienced substantial declines due to generic erosion.
Research and development expenses increased 17%, largely due to $410 million in IPRD impairment charges for a radiopharmaceutical and an oncology asset. Amortization of acquired intangible assets decreased significantly as Pomalyst was fully amortized. The company's strategic productivity initiative aims for $2.0 billion in annual cost savings by 2027. The IRA continues to pose a risk, with Eliquis, Pomalyst, and Orencia subject to government-set prices or negotiation. Operating cash flow decreased due to lower Eliquis customer receipts and higher litigation disbursements. |
|---|
| Feb 11, 2026 | business | Bristol Myers Squibb is navigating significant revenue declines in several key legacy products due to generic erosion and the redesign of the Medicare Part D program. In 2025, U.S. revenues for Revlimid, an oral immunomodulatory drug for multiple myeloma, decreased 49%, with international revenues falling 46% as generic lenalidomide entered major markets. Pomalyst/Imnovid, also for multiple myeloma, saw U.S. revenues drop 13% and international revenues 54%, with generic pomalidomide entering the EU and expected in the U.S. by March 2026. Sprycel, for CML, experienced a 70% U.S. revenue decrease and 36% internationally, following generic dasatinib entry in the U.S., EU, and Japan. Abraxane, a chemotherapy for various cancers, also saw a 78% U.S. revenue reduction.
To counter these losses, BMY is focused on its late-stage pipeline and recent approvals. Abecma and Breyanzi, CAR-T therapies, received label updates and new approvals for hematological malignancies like follicular lymphoma, mantle cell lymphoma, and marginal zone lymphoma. Opdivo and Opdivo + Yervoy secured approvals for non-small cell lung cancer, colorectal cancer, and hepatocellular carcinoma, with a subcutaneous Opdivo formulation also approved. Camzyos, for obstructive hypertrophic cardiomyopathy, gained Japan approval and FDA label updates, though a non-obstructive HCM trial failed. Sotyktu demonstrated positive Phase III results for psoriatic arthritis and long-term efficacy in plaque psoriasis. However, some pipeline setbacks occurred, including the discontinuation of the milvexian ACS trial and failures for Opdualag in melanoma and Reblozyl in myelofibrosis-associated anemia. The company continues strategic investments in R&D and M&A to drive future growth. |
|---|
